Subcutaneous IGF-1 is not beneficial in 2-year ALS trial

被引：194

作者：

Sorenson, E. J. ^{[1
]}

Windbank, A. J. ^{[1
]}

Mandrekar, J. N. ^{[1
]}

Bamlet, W. R. ^{[1
]}

Appel, S. H. ^{[2
]}

Armon, C. ^{[3
]}

Barkhaus, P. E. ^{[4
]}

Bosch, P. ^{[5
]}

Boylan, K. ^{[6
]}

David, W. S. ^{[7
]}

Feldman, E. ^{[8
]}

Glass, J. ^{[9
]}

Gutmann, L. ^{[10
]}

Katz, J. ^{[11
]}

King, W. ^{[12
]}

Luciano, C. A. ^{[13
]}

McCluskey, L. F. ^{[14
]}

Nash, S. ^{[12
]}

Newman, D. S. ^{[15
]}

Pascuzzi, R. M. ^{[16
]}

Pioro, E. ^{[17
]}

Sams, L. J. ^{[18
]}

Scelsa, S. ^{[19
]}

Simpson, E. P. ^{[2
]}

Subramony, S. H. ^{[20
]}

Tiryaki, E. ^{[7
]}

Thornton, C. A. ^{[21
]}

机构：

[1] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA

[2] Methodist Hosp, Houston, TX 77030 USA

[3] Baystate Med Ctr, Springfield, MA USA

[4] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[5] Mayo Clin Arizona, Scottsdale, AZ USA

[6] Mayo Clin Jacksonville, Jacksonville, FL 32224 USA

[7] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA

[8] Univ Michigan, Med Ctr, Ann Arbor, MI USA

[9] Emory Univ, Med Ctr, Atlanta, GA 30322 USA

[10] W Virginia Univ, Med Ctr, Morgantown, WV 26506 USA

[11] Forbes Norris MDA ALS Res Ctr, San Francisco, CA USA

[12] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA

[13] Univ Puerto Rico, San Juan, PR 00936 USA

[14] Penn Neurol Inst, Philadelphia, PA USA

[15] Henry Ford Med Ctr, Detroit, MI USA

[16] Indiana Univ, Med Ctr, Indianapolis, IN USA

[17] Cleveland Clin, Cleveland, OH USA

[18] Univ Cincinnati, Cincinnati, OH 45221 USA

[19] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA

[20] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA

[21] Univ Rochester, Med Ctr, Rochester, NY 14627 USA

来源：

NEUROLOGY | 2008年 / 71卷 / 22期

关键词：

D O I：

10.1212/01.wnl.0000335970.78664.36

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: Previous human clinical trials of insulin-like growth factor type I (IGF-1) in amyotrophic lateral sclerosis (ALS) have been inconsistent. This phase III, randomized, double-blind, placebo-controlled study was undertaken to address whether IGF-1 benefited patients with ALS. Methods: A total of 330 patients from 20 medical centers were randomized to receive 0.05 mg/kg body weight of human recombinant IGF-1 given subcutaneously twice daily or placebo for 2 years. The primary outcome measure was change in their manual muscle testing score. Secondary outcome measures included tracheostomy-free survival and rate of change in the revised ALS functional rating scale. Intention to treat analysis was used. Results: There was no difference between treatment groups in the primary or secondary outcome measures after the 2-year treatment period. Conclusions: Insulin-like growth factor type I does not provide benefit for patients with amyotrophic lateral sclerosis. Neurology (R) 2008; 71: 1770-1775

引用

页码：1770 / 1775

页数：6

共 20 条

[11] Effect of recombinant human insulin-like growth factor-I on progression of ALS - A placebo-controlled study [J].